Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications
- 1.1k Downloads
Oxytocin (OT) acts as a neuromodulator/neurotransmitter within the central nervous system (CNS) and regulates a diverse range of CNS functions. Notably, evidence from studies in females has revealed an important role for OT in regulating anxiety behavior.
The objective of this study was to examine the effects of OT on both behavioral and autonomic parameters of the anxiety response in male mice using three pharmacologically validated preclinical models of anxiety: the four-plate test (FPT), elevated zero maze (EZM), and stress-induced hyperthermia (SIH).
In the FPT, both peripherally (3–30 mg/kg i.p.) and centrally (1–10 μg i.c.v.) administered OT produced dose-dependent increases in punished crossings, indicating an anxiolytic-like effect. The effects of centrally administered OT in the FPT were blocked with peripheral administration of a brain-penetrant OT receptor (OTR) antagonist WAY-162720 (30 mg/kg i.p.), and the effects of peripherally administered OT were blocked with central administration of a non-penetrant OTR antagonist L-371,257, suggesting OT acts centrally. In the EZM, centrally administered OT (0.1–1.0 μg, i.c.v.) produced significant increases in the percentage time spent in the open quadrants of the maze, comparable to alprazolam (0.5–1.0 μg, i.c.v.). In SIH, OT (1–10 mg/kg i.p.) dose-dependently attenuated stress-induced increases in core body temperature, comparable to the reference anxiolytic chlordiazepoxide (CDP) (10 mg/kg i.p.).
These results provide specific behavioral and autonomic evidence of anxiolytic-like effects for oxytocin in males and, together with previously reported observations in females, suggest the potential utility of OTR agonism as a therapeutically relevant mechanism of action for novel anxiolytics in both sexes.
KeywordsOxytocin Vasopressin Anxiety Stress Depression Hyperthermia Autonomic Anxiolytic Benzodiazepine
- DSM-IV-TR (2000) Diagnostic and statistical manual of mental disorders (DSM-IV-TR), 4th edn (text revision). American Psychiatric AssociationGoogle Scholar
- Numan M, Insel TR (2003) The neurobiology of parental behavior. Springer, Berlin Heidelberg New YorkGoogle Scholar
- Ring RH (2005) The central vasopressinergic and oxytocinergic systems as targets for psychiatric drug development neurohypophyseal hormones: from genomics and physiology to disease. American Physiological Society, Steamboat Springs, Colorado, p 162Google Scholar
- Williams PD, Clineschmidt BV, Erb JM, Freidinger RM, Guidotti MT, Lis EV, Pawluczyk JM, Pettibone DJ, Reiss DR, Veber DF et al (1995) 1-(1-[4-[(N-Acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. J Med Chem 38:4634–4636CrossRefPubMedGoogle Scholar